-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
3 Stocks Under $3 Insiders Are Aggressively Buying
3 Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Rubius Therapeutics
- The Trade: Rubius Therapeutics, Inc. (NASDAQ:RUBY) Director David Epstein acquired a total of 30,000 shares at an average price of $1.44. To acquire these shares, it cost $43.33 thousand.
- What's Happening: Rubius Therapeutics recently announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.
- What Rubius Therapeutics Does: Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Adverum Biotechnologies
- The Trade: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO, President and Director Laurent Fischer acquired a total of 25,000 shares at an average price of $1.11. The insider spent around $27.8 thousand to buy those shares.
- What's Happening: Adverum Biotechnologies recently received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).
- What Adverum Biotechnologies Does: Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company.
Also check this: Insiders Buy More Than $15M Of 3 Stocks
Don't forget to check out our premarket coverage here .
Anixa Biosciences
- The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) President Michael Catelani acquired a total of 5,500 shares at an average price of $2.66. To acquire these shares, it cost around $14.63 thousand.
- What's Happening: Anixa Biosciences, last month, announced the initiation of its ovarian cancer CAR-T Phase 1 trial at Moffitt Cancer Center.
- What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer.
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
美國原油期貨週一走低。與此同時,投資者關注的是一些值得注意的內幕交易。
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
當內部人士買賣股票時,這表明了他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易員可以在他們的整體投資或交易決策中考慮這一因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近幾筆值得注意的細價股內幕交易。欲瞭解更多信息,請查看Benzinga的內幕交易平臺。
Rubius Therapeutics
Rubius治療公司
- The Trade: Rubius Therapeutics, Inc. (NASDAQ:RUBY) Director David Epstein acquired a total of 30,000 shares at an average price of $1.44. To acquire these shares, it cost $43.33 thousand.
- What's Happening: Rubius Therapeutics recently announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.
- What Rubius Therapeutics Does: Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
- 行業: Rubius治療公司納斯達克(股票代碼:RUBY)董事大衞·愛潑斯坦以1.44美元的平均價格收購了總計30,000股新浪微博。收購這些股份,花費了433.3萬美元。
- 正在發生的事情:Rubius治療公司最近宣佈了正在進行的RTX-240治療晚期實體腫瘤1/2期試驗的1期單一療法的最新數據。
- Rubius Treateutics的作用:Rubius治療公司開發紅細胞療法(RCT),用於治療罕見疾病、癌症和自身免疫性疾病的患者。
Adverum Biotechnologies
Adverum生物技術公司
- The Trade: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO, President and Director Laurent Fischer acquired a total of 25,000 shares at an average price of $1.11. The insider spent around $27.8 thousand to buy those shares.
- What's Happening: Adverum Biotechnologies recently received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).
- What Adverum Biotechnologies Does: Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company.
- 《貿易》: Adverum生物技術公司納斯達克(Sequoia Capital:ADVM)首席執行官兼總裁兼董事總裁費希爾以1.11美元的平均價格收購了總計25,000股董事股票。這位內部人士花了大約278千美元購買了這些股票。
- 發生了什麼事?:Adverum生物技術公司最近通過一次C型會議收到了FDA關於其計劃中的ADVM-022治療濕性老年性黃斑變性(濕性AMD)的第二階段試驗的書面反饋。
- Adverum BioTechnologies做了什麼:Adverum BioTechnologies Inc.是一家總部位於美國的臨牀階段基因治療公司。
Also check this: Insiders Buy More Than $15M Of 3 Stocks
還可以查一下:內部人士購買了3只股票,價值超過1500萬美元
Don't forget to check out our premarket coverage here .
別忘了在這裏查看我們的售前報道。
Anixa Biosciences
Anixa生物科學
- The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) President Michael Catelani acquired a total of 5,500 shares at an average price of $2.66. To acquire these shares, it cost around $14.63 thousand.
- What's Happening: Anixa Biosciences, last month, announced the initiation of its ovarian cancer CAR-T Phase 1 trial at Moffitt Cancer Center.
- What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer.
- 《貿易》: Anixa生物科學公司納斯達克(股票代碼:ANIX)總裁邁克爾·卡塔拉尼以2.66美元的平均價格收購了總計5,500股票。收購這些股份的成本約為146.3萬美元。
- 發生了什麼事?:Anixa Biosciences上個月宣佈在莫菲特癌症中心啟動其卵巢癌CAR-T階段1試驗。
- Anixa生物科學公司做了什麼:Anixa Biosciences Inc.是一家專注於癌症的生物技術公司,致力於利用人體免疫系統抗擊癌症。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧